WO2005016288A3 - Methods and compositions for treatment of viral diseases - Google Patents
Methods and compositions for treatment of viral diseases Download PDFInfo
- Publication number
- WO2005016288A3 WO2005016288A3 PCT/US2004/005952 US2004005952W WO2005016288A3 WO 2005016288 A3 WO2005016288 A3 WO 2005016288A3 US 2004005952 W US2004005952 W US 2004005952W WO 2005016288 A3 WO2005016288 A3 WO 2005016288A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- reducing
- infection
- treating
- viral
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- 230000003612 virological effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 3
- MRKKUGDWODATMF-SECBINFHSA-N (2R)-2-[[5-methoxy-2-(methylamino)pyrimidin-4-yl]amino]hexan-1-ol Chemical compound CCCC[C@H](CO)Nc1nc(NC)ncc1OC MRKKUGDWODATMF-SECBINFHSA-N 0.000 abstract 1
- 208000007887 Alphavirus Infections Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 229940124257 Interferon receptor agonist Drugs 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 206010057293 West Nile viral infection Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides methods of treating alphavirus infection; methods of treating hepatitis C virus (HCV) infection; methods of treating West Nile virus infection; methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from viral infection. The methods generally involve administering to a subject in need thereof an effective dosage of an interferon receptor agonist, either alone or in combination therapy with ribavirin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04775811A EP1601368A2 (en) | 2003-02-28 | 2004-02-26 | Methods and compositions for treatment of viral diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45135103P | 2003-02-28 | 2003-02-28 | |
| US60/451,351 | 2003-02-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005016288A2 WO2005016288A2 (en) | 2005-02-24 |
| WO2005016288A3 true WO2005016288A3 (en) | 2005-07-07 |
Family
ID=34192980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/005952 WO2005016288A2 (en) | 2003-02-28 | 2004-02-26 | Methods and compositions for treatment of viral diseases |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP1601368A2 (en) |
| WO (1) | WO2005016288A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129267A2 (en) | 2006-05-10 | 2007-11-15 | Koninklijke Philips Electronics N.V. | Automatic external defibrillator with enhanced clarity of audible prompts |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| CN103826627B (en) | 2011-10-21 | 2016-02-24 | 艾伯维公司 | Comprise the purposes of compositions in the medicine of preparation treatment HCV of at least two kinds of direct antiviral agent and ribavirin |
| EA201892448A1 (en) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
-
2004
- 2004-02-26 EP EP04775811A patent/EP1601368A2/en not_active Withdrawn
- 2004-02-26 WO PCT/US2004/005952 patent/WO2005016288A2/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
Non-Patent Citations (5)
| Title |
|---|
| ARASE Y. ET AL.: "Annual review shokaki", January 1998 (1998-01-01), pages 237 - 242 * |
| KOTENKO S.V. ET AL.: "INF-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex", NATURE IMMUNOLOGY, vol. 4, no. 1, January 2003 (2003-01-01), pages 69 - 77, XP008040607 * |
| OKU H. ET AL.: "Pirfenidone suppresses tumor necrosis factor alfa, enhances interleukine-10 and protects mice from endotoxic shock", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 226, no. 103, June 2002 (2002-06-01), pages 167 - 176 * |
| SHAPPARD P. ET AL.: "IL-28, IL-29 and their class II cytokine receptor IL-28R", NATURE IMMUNOLOGY, vol. 4, no. 1, January 2003 (2003-01-01), pages 63 - 68, XP002261756 * |
| SUZUKI H. ET AL.: "Therapy of viral hepatitis in Japan-present and future", ANTI-BIOTICS & CHEMOTHERAPY, vol. 15, no. 3, 1999, pages 353 - 360 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005016288A2 (en) | 2005-02-24 |
| EP1601368A2 (en) | 2005-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006016930A3 (en) | Methods for treating hcv infection | |
| WO2005013917A3 (en) | Combination therapy for treating alphavirus infection and liver fibrosis | |
| Pawlotsky et al. | Antiviral action of ribavirin in chronic hepatitis C | |
| Mauss et al. | A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance | |
| JP2008518943A5 (en) | ||
| WO2005067454A3 (en) | Combination therapy for treating hepatitis c virus infection | |
| Buti et al. | Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases | |
| WO2003026589A3 (en) | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides | |
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| WO2006130553A3 (en) | Hcv protease inhibitors | |
| SK155997A3 (en) | Use of ribavirin and interferon alpha for the treatment of hepatitis c | |
| RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
| MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
| WO2002089780A3 (en) | Antiviral compounds | |
| RU2010153688A (en) | BODY DOSAGE MODE | |
| WO2005110455A3 (en) | Combination therapy for treating hepatitis virus infection | |
| WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
| WO2005097618A3 (en) | Low dose therapy for treating viral infections | |
| WO2000032177A3 (en) | Use of 17-ketosteroids in the treatment of hepatitis c virus and other togavirus infections | |
| UA95299C2 (en) | Prophylactic or therapeutic agent for viral disease caused by hepatitis c virus | |
| WO2006131566A3 (en) | Oral ribavirin pharmaceutical compositions | |
| WO2003030613A3 (en) | Methods of treating liver fibrosis and hepatitis c virus infection | |
| WO2004006848A3 (en) | Combination therapies with ftc for the treatment of hepatitis b virus infection | |
| WO2003017943A3 (en) | Therapeutic compositions and methods for treating viral infection | |
| DK1311279T3 (en) | Treatment of hepatitis C with thymosin, interferon and ribavirin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004775811 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004775811 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2004775811 Country of ref document: EP |